XORTX Therapeutics Inc. (XRTX)

$1.01

-0.09 (-8.18%)
Rating:
Recommendation:
-
Symbol XRTX
Price $1.01
Beta 0.459
Volume Avg. 0.51M
Market Cap 13.020M
Shares () -
52 Week Range 0.895-5.89
1y Target Est -
DCF Unlevered XRTX DCF ->
DCF Levered XRTX LDCF ->
ROE -
ROA -
Operating Margin -
Debt / Equity -
P/E -
P/B -
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest XRTX news


Healthcare
Biotechnology
NASDAQ Capital Market

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.